Is GRI Bio, Inc. (GRI) a Buy, Sell, or Hold?
GRI Bio, Inc.
NASDAQ:GRI
$1.62 USD
$0.05 (3.18%)
- Volume
- 33.32K
- Average Volume
- 67.18K
- Market Capitalization
- $145.53K
- P/E Ratio
- -0.02
- Dividend Yield
- 0.00%
- Price Target
- $
- Year High
- $80.36
- Year Low
- $1.53
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $14.21
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | W. Marc Hertz |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | GRI |
| CUSIP | 3622AW502 |
| CIK | 0001824293 |
| Web | https://www.gribio.com |
| Phone | 619 400 1170 |
| Currency | USD |
| Employees | 4 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.01 |
| Payout Ratio | 0.00 |
| Current Ratio | 14.21 |
| Quick Ratio | 14.21 |
| Cash Ratio | 13.91 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -9.78 |
| Price / Cash Flow | -0.01 |
| Price / Book | 0.19 |
Price Target and Rating
| Average Stock Price Forecast | $ |
| High Stock Price Forecast | $ |
| Low Stock Price Forecast | $ |
| Forecast Upside/Downside | % |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 2 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-121.8 |
| Trailing P/E Ratio | -0.02 |
| PEG Ratio | 0.00 |
| P/E Growth | 0.00 |
| Net Income | $-11.96M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -199.52% |
| Return on Assets | -96.20% |
Financials Score
| AltmanZ Score | -8.59 |
| Piotroski Score | 1.00 |
| Working Capital | 10.48M |
| Total Assets | 11.34M |
| Ebit | -10.92M |
| Market Cap | 145.53K |
| Total Liabilities | 794K |
Poll Results
About GRI Bio, Inc. (NASDAQ:GRI) Stock
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio ... , Inc. was founded in 2009 and is based in LA Jolla, California.
Banner Bank Releases New Corporate Responsibility Report
2026-07-14 14:00:00
Today, Banner Bank released its 2025 Corporate Responsibility Report. The report identifies ongoing practices and recent accomplishments that contribute to crea
Asbury Automotive Group Named in TIME America's Best Companies 2026 List
2026-07-09 09:00:00
Asbury Automotive Group, Inc. (NYSE: ABG), one of the largest automotive retail and service companies in the U.S, is proud to be recognized on TIME's list of A
Luxshare Precision Releases 2025 Sustainability Report
2026-06-23 04:00:00
Luxshare Precision Releases 2025 Sustainability Report PR Newswire NEW YORK, June 23, 2026
2026-06-22 12:00:00
CROWN HOLDINGS ANNOUNCES PUBLICATION OF ITS 2025 SUSTAINABILITY REPORT "DELIVERING SUSTAINABILITY", HIGHLIGHTING KEY MILESTONES AND PROGRESS TO
2026-06-18 08:31:00
Designation highlights significant regulatory milestone and provides a potential pathway to seven years of U.S. market exclusivity
2026-06-18 08:31:00
Designation highlights significant regulatory milestone and provides a potential pathway to seven years of U. S. market exclusivity LA JOLLA, CA, June 18, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) ("GRI Bio" or the "Company"), a biotechnology company developing innovative therapies for inflammatory, fibrotic and autoimmune diseases, today announced that the U.
The Toro Company Publishes 2025 Global Sustainability Impact Report
2026-06-10 09:00:00
The Toro Company (NYSE: TTC), a leading global provider of solutions for the outdoor environment, today released its fiscal 2025 Sustainability Impact Report.
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase
2026-05-18 09:15:00
Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer, on Wednesday, May 20, 2026 Register for the event here LA JOLLA, CA, May 18, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that Marc Hertz, PhD, Chief Executive Officer of GRI Bio, will participate in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase being held virtually on Wednesday, May 20, 2026.
Frequently Asked Questions
-
What is the current GRI Bio, Inc. (GRI) stock price?
-
GRI Bio, Inc.(NASDAQ:GRI) stock price is $1.62 in the last trading session. During the trading session, GRI stock reached the peak price of $80.36 while $1.53 was the lowest point it dropped to. The percentage change in GRI stock occurred in the recent session was 3.18% while the dollar amount for the price change in GRI stock was $0.05.
-
GRI's industry and sector of operation?
-
The NASDAQ listed GRI is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of GRI?
-
Vipin Kumar | Co-Founder & Chief Scientific Officer
W. Marc Hertz | Co-Founder, Chief Executive Officer, President & Director
Leanne Kelly | Chief Financial Officer & Corporate Secretary
Albert Agro | Co-Founder & Chief Medical Officer
| -
How many employees does GRI have?
-
Number of GRI employees currently stands at 4. GRI operates from 2223 Avenida de la Playa, La Jolla, CA 92037, US.
-
Link for GRI official website?
-
Official Website of GRI is: https://www.gribio.com
-
How do I contact GRI?
-
GRI could be contacted at phone #619 400 1170 and can also be accessed through its website. GRI operates from 2223 Avenida de la Playa, La Jolla, CA 92037, US.
-
How many shares of GRI are traded daily?
-
The average number of GRI shares traded daily for last 3 months was 67.18K.
-
What is the market cap of GRI currently?
-
The market value of GRI currently stands at $145.53K with its latest stock price at $1.62